Immunophenotypic and Quantitative Impacts of Ibrutinib and Chlorambucil on Circulating Immune Cells in CLL

Conference Correspondent - ASCO 2017 - Chronic Lymphocytic Leukemia

Ibrutinib, a once-daily inhibitor of Bruton’s tyrosine kinase, is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL). After the phase 3 RESONATE-2 trial, ibrutinib received approval as frontline therapy in treatment-naïve patients with CLL. In this study, ibrutinib reduced the risk of progression or death by 84% compared with chlorambucil. In an effort to better understand the mechanism by which these agents act on the immune system, quantitative changes in circulating cells were studied throughout the first year of treatment.

Immunophenotypic analyses were performed on a total of 80 patients to assess lymphoid and myeloid cells of treatment-naïve patients with CLL who received 420 mg ibrutinib once daily (n = 50) or chlorambucil 0.5 to 0.8 mg/kg twice per month (n = 30). The researchers found substantial differences in the immunophenotypic and quantitative impacts of the 2 therapies during the first year of treatment. Ibrutinib mainly reduced B-cells (90%), myeloid-derived suppressor cells (61%), and certain T-cells—specifically, long-term activated T-cells, PD-1+ T-cells, regulatory T-cells, and effector T-cells (27%-52%)—while showing limited effect on naïve T-cells, stem-cell memory T-cells, central memory T-cells, and natural killer (NK) cells. Classical monocytes were increased (+187%), while nonclassical monocytes did not increase. Conversely, chlorambucil progressively reduced circulating B-, T-, NK, and NKT cells, myeloid-derived suppressor cells, and monocytes by 69% to 99%. All development stages of CD4+ and CD8+ T-cells, except stem-cell memory T-cells, decreased by 51% to 90%. Long-term activated T-cells, however, were not affected throughout a full year of treatment with chlorambucil.

The data indicate that ibrutinib targets cells involved in tumor growth, while preserving cells that are important for mounting antitumor responses. Chlorambucil was found to act less specifically than ibrutinib on most immune-cell subsets in circulation. These data help to explain the differential clinical activity and side-effect profiles for ibrutinib and chlorambucil.

Solman I, et al. ASCO Abstract 7524.

Related Items
iFCG for Previously Untreated Patients with CLL with Mutated IGHV and Non-Del(17p)
Conference Correspondent published on June 9, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia
Results of a Phase 2 Multicenter Study of Obinutuzumab plus Bendamustine in Patients with Previously Untreated CLL
Conference Correspondent published on June 9, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia
Phase 1 Dose Escalation of Ibrutinib and Buparlisib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Mantle-Cell Lymphoma, and Follicular Lymphoma
Conference Correspondent published on June 9, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia
KI Intolerance Study: A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with CLL Intolerant to Prior Bruton’s Tyrosine Kinase or PI3Kδ Inhibitor Therapy
Conference Correspondent published on June 9, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia
A Phase 1a/1b Study of a Novel BTK Inhibitor and Combination Products with Everolimus and Pomalidomide in Patients with CLL or Other B-Cell Lymphomas
Conference Correspondent published on June 8, 2017 in ASCO 2017 - Chronic Lymphocytic Leukemia
Last modified: June 7, 2017
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME